Reni Benjamin
Stock Analyst at Citizens
(1.35)
# 3,691
Out of 5,113 analysts
162
Total ratings
37.68%
Success rate
-14.3%
Average return
Main Sectors:
Stocks Rated by Reni Benjamin
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ALLO Allogene Therapeutics | Upgrades: Market Outperform | $5 | $1.45 | +244.83% | 9 | Jan 9, 2026 | |
| CMPX Compass Therapeutics | Initiates: Market Outperform | $10 | $6.16 | +62.34% | 1 | Dec 3, 2025 | |
| BCYC Bicycle Therapeutics | Maintains: Market Outperform | $10 → $12 | $6.58 | +82.37% | 15 | Oct 31, 2025 | |
| INBX Inhibrx Biosciences | Reiterates: Market Perform | n/a | $73.98 | - | 10 | May 15, 2025 | |
| CUE Cue Biopharma | Reiterates: Market Outperform | $2 | $0.37 | +439.08% | 5 | Apr 2, 2025 | |
| BCAB BioAtla | Maintains: Market Outperform | $5 → $1 | $0.31 | +222.06% | 9 | Mar 31, 2025 | |
| INCY Incyte | Reiterates: Market Perform | n/a | $101.18 | - | 28 | Mar 11, 2025 | |
| ACET Adicet Bio | Reiterates: Market Perform | n/a | $8.45 | - | 5 | Mar 7, 2025 | |
| HOWL Werewolf Therapeutics | Maintains: Market Outperform | $12 → $4 | $0.71 | +460.62% | 5 | Jan 14, 2025 | |
| CGEN Compugen | Maintains: Market Outperform | $8 → $4 | $1.95 | +105.13% | 1 | Aug 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $1.21 | - | 2 | Dec 3, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Market Perform | n/a | $6.85 | - | 3 | Jun 14, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $11 → $10 | $16.33 | -38.76% | 2 | Oct 12, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Market Outperform | $23 | $15.61 | +47.34% | 11 | Jan 20, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $5 | $4.75 | +5.26% | 6 | Jun 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $28 | $8.04 | +248.26% | 11 | Jun 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Perform | n/a | $7.09 | - | 2 | Jun 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $40 | $15.64 | +155.75% | 4 | Jun 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $2.75 | - | 11 | May 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $4 | $1.97 | +103.05% | 5 | Apr 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $7 → $8 | $9.55 | -16.23% | 1 | Mar 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $60 | $44.98 | +33.39% | 1 | Mar 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Perform | n/a | $9.34 | - | 1 | Feb 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $315 | $189.12 | +66.56% | 1 | Feb 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Perform | n/a | $79.78 | - | 1 | Feb 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $265 | $260.86 | +1.59% | 1 | Feb 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Outperform | $28 → $17 | $3.97 | +328.21% | 3 | Nov 10, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Outperform | n/a | $11.01 | - | 4 | Jun 14, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Market Perform | n/a | $1.80 | - | 2 | Feb 7, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Outperform | $22 → $12 | $30.31 | -60.41% | 1 | Sep 25, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $21.32 | - | 1 | Nov 15, 2017 |
Allogene Therapeutics
Jan 9, 2026
Upgrades: Market Outperform
Price Target: $5
Current: $1.45
Upside: +244.83%
Compass Therapeutics
Dec 3, 2025
Initiates: Market Outperform
Price Target: $10
Current: $6.16
Upside: +62.34%
Bicycle Therapeutics
Oct 31, 2025
Maintains: Market Outperform
Price Target: $10 → $12
Current: $6.58
Upside: +82.37%
Inhibrx Biosciences
May 15, 2025
Reiterates: Market Perform
Price Target: n/a
Current: $73.98
Upside: -
Cue Biopharma
Apr 2, 2025
Reiterates: Market Outperform
Price Target: $2
Current: $0.37
Upside: +439.08%
BioAtla
Mar 31, 2025
Maintains: Market Outperform
Price Target: $5 → $1
Current: $0.31
Upside: +222.06%
Incyte
Mar 11, 2025
Reiterates: Market Perform
Price Target: n/a
Current: $101.18
Upside: -
Adicet Bio
Mar 7, 2025
Reiterates: Market Perform
Price Target: n/a
Current: $8.45
Upside: -
Werewolf Therapeutics
Jan 14, 2025
Maintains: Market Outperform
Price Target: $12 → $4
Current: $0.71
Upside: +460.62%
Compugen
Aug 8, 2022
Maintains: Market Outperform
Price Target: $8 → $4
Current: $1.95
Upside: +105.13%
Dec 3, 2019
Downgrades: Market Perform
Price Target: n/a
Current: $1.21
Upside: -
Jun 14, 2019
Reinstates: Market Perform
Price Target: n/a
Current: $6.85
Upside: -
Oct 12, 2018
Maintains: Outperform
Price Target: $11 → $10
Current: $16.33
Upside: -38.76%
Jan 20, 2026
Upgrades: Market Outperform
Price Target: $23
Current: $15.61
Upside: +47.34%
Jun 24, 2025
Reiterates: Market Outperform
Price Target: $5
Current: $4.75
Upside: +5.26%
Jun 4, 2025
Reiterates: Market Outperform
Price Target: $28
Current: $8.04
Upside: +248.26%
Jun 2, 2025
Reiterates: Market Perform
Price Target: n/a
Current: $7.09
Upside: -
Jun 2, 2025
Reiterates: Market Outperform
Price Target: $40
Current: $15.64
Upside: +155.75%
May 9, 2025
Downgrades: Market Perform
Price Target: n/a
Current: $2.75
Upside: -
Apr 29, 2025
Reiterates: Market Outperform
Price Target: $4
Current: $1.97
Upside: +103.05%
Mar 12, 2025
Maintains: Market Outperform
Price Target: $7 → $8
Current: $9.55
Upside: -16.23%
Mar 3, 2025
Reiterates: Market Outperform
Price Target: $60
Current: $44.98
Upside: +33.39%
Feb 6, 2025
Reiterates: Market Perform
Price Target: n/a
Current: $9.34
Upside: -
Feb 6, 2025
Reiterates: Market Outperform
Price Target: $315
Current: $189.12
Upside: +66.56%
Feb 6, 2025
Reiterates: Market Perform
Price Target: n/a
Current: $79.78
Upside: -
Feb 6, 2025
Reiterates: Market Outperform
Price Target: $265
Current: $260.86
Upside: +1.59%
Nov 10, 2020
Downgrades: Outperform
Price Target: $28 → $17
Current: $3.97
Upside: +328.21%
Jun 14, 2019
Reinstates: Outperform
Price Target: n/a
Current: $11.01
Upside: -
Feb 7, 2019
Upgrades: Market Perform
Price Target: n/a
Current: $1.80
Upside: -
Sep 25, 2018
Downgrades: Outperform
Price Target: $22 → $12
Current: $30.31
Upside: -60.41%
Nov 15, 2017
Downgrades: Market Perform
Price Target: n/a
Current: $21.32
Upside: -